These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 36881782)

  • 1. MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis.
    Mascarenhas J; Kremyanskaya M; Patriarca A; Palandri F; Devos T; Passamonti F; Rampal RK; Mead AJ; Hobbs G; Scandura JM; Talpaz M; Granacher N; Somervaille TCP; Hoffman R; Wondergem MJ; Salama ME; Colak G; Cui J; Kiladjian JJ; Vannucchi AM; Verstovsek S; Curto-García N; Harrison C; Gupta V
    J Clin Oncol; 2023 Nov; 41(32):4993-5004. PubMed ID: 36881782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis.
    Gupta V; Mascarenhas J; Kremyanskaya M; Rampal RK; Talpaz M; Kiladjian JJ; Vannucchi AM; Verstovsek S; Colak G; Dey D; Harrison C
    Blood Adv; 2023 Sep; 7(18):5421-5432. PubMed ID: 37530627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
    Harrison CN; Gupta VK; Gerds AT; Rampal R; Verstovsek S; Talpaz M; Kiladjian JJ; Mesa R; Kuykendall AT; Vannucchi AM; Palandri F; Grosicki S; Devos T; Jourdan E; Wondergem MJ; Al-Ali HK; Buxhofer-Ausch V; Alvarez-Larrán A; Patriarca A; Kremyanskaya M; Mead AJ; Akhani S; Sheikine Y; Colak G; Mascarenhas J
    Future Oncol; 2022 Sep; 18(27):2987-2997. PubMed ID: 35950489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
    Pemmaraju N; Garcia JS; Potluri J; Harb JG; Sun Y; Jung P; Qin QQ; Tantravahi SK; Verstovsek S; Harrison C
    Lancet Haematol; 2022 Jun; 9(6):e434-e444. PubMed ID: 35576960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy.
    Harrison CN; Garcia JS; Somervaille TCP; Foran JM; Verstovsek S; Jamieson C; Mesa R; Ritchie EK; Tantravahi SK; Vachhani P; O'Connell CL; Komrokji RS; Harb J; Hutti JE; Holes L; Masud AA; Nuthalapati S; Potluri J; Pemmaraju N
    J Clin Oncol; 2022 May; 40(15):1671-1680. PubMed ID: 35180010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
    Mesa RA; Kiladjian JJ; Catalano JV; Devos T; Egyed M; Hellmann A; McLornan D; Shimoda K; Winton EF; Deng W; Dubowy RL; Maltzman JD; Cervantes F; Gotlib J
    J Clin Oncol; 2017 Dec; 35(34):3844-3850. PubMed ID: 28930494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
    Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
    JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
    Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pelabresib (CPI-0610): An Exciting Novel Drug for the Treatment of Myelofibrosis.
    Ferreira Gomes G; Harrison C
    Curr Hematol Malig Rep; 2023 Aug; 18(4):113-120. PubMed ID: 37195585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
    Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger M; Miller C; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner E; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Koumenis IL; Sun W; Sandor V; Kantarjian HM
    N Engl J Med; 2012 Mar; 366(9):799-807. PubMed ID: 22375971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
    Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
    N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
    Couban S; Benevolo G; Donnellan W; Cultrera J; Koschmieder S; Verstovsek S; Hooper G; Hertig C; Tandon M; Dimier N; Malhi V; Passamonti F
    J Hematol Oncol; 2018 Sep; 11(1):122. PubMed ID: 30249277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naïve patients with myelofibrosis: Results of a phase II trial.
    Zhang Y; Zhou H; Jiang Z; Wu D; Zhuang J; Li W; Jiang Q; Wang X; Huang J; Zhu H; Yang L; Du X; Li F; Xia R; Zhang F; Hu J; Li Y; Hu Y; Liu J; Jin C; Sun K; Zhou Z; Wu L; Yu W; Jin J
    Am J Hematol; 2022 Dec; 97(12):1510-1519. PubMed ID: 36054786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes.
    Mascarenhas JO; Verstovsek S
    Cancer; 2022 Jul; 128(14):2717-2727. PubMed ID: 35385124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial.
    Shimoda K; Komatsu N; Matsumura I; Ikeda K; Hino M; Hidaka M; Maeda Y; Kondo T; Fujisaki T; Shoshi K; Azuma K; Fukushima R; Kawashima J; Kosugi H
    Int J Hematol; 2024 Sep; 120(3):314-324. PubMed ID: 39110143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study.
    Zhang Y; Zhou H; Duan M; Gao S; He G; Jing H; Li J; Ma L; Zhu H; Chang C; Du X; Hong M; Li X; Liu Q; Wang W; Xu N; Yang H; Lu B; Yin H; Wu L; Suo S; Zhao Q; Xiao Z; Jin J
    Am J Hematol; 2023 Oct; 98(10):1588-1597. PubMed ID: 37470365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study.
    Talpaz M; Erickson-Viitanen S; Hou K; Hamburg S; Baer MR
    J Hematol Oncol; 2018 Aug; 11(1):101. PubMed ID: 30086777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors.
    Gangat N; Tefferi A
    Am J Hematol; 2024 May; 99(5):978-981. PubMed ID: 38332640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.
    Talpaz M; Paquette R; Afrin L; Hamburg SI; Prchal JT; Jamieson K; Terebelo HR; Ortega GL; Lyons RM; Tiu RV; Winton EF; Natrajan K; Odenike O; Claxton D; Peng W; O'Neill P; Erickson-Viitanen S; Leopold L; Sandor V; Levy RS; Kantarjian HM; Verstovsek S
    J Hematol Oncol; 2013 Oct; 6(1):81. PubMed ID: 24283202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.
    Gupta V; Oh S; Devos T; Dubruille V; Catalano J; Somervaille TCP; Platzbecker U; Giraldo P; Kosugi H; Sacha T; Mayer J; Illes A; Ellis C; Wang Z; Gonzalez Carreras FJ; Strouse B; Mesa R
    Leuk Lymphoma; 2024 Jul; 65(7):965-977. PubMed ID: 38501751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.